Allergan urges shareholders to reject Valeant's $52B hostile takeover bid

Allergan urges its shareholders to reject Valeant Pharmaceutical's hostile takeover bid, valued at nearly $52 billion, saying the deal significantly undervalues Allergan.

Valeant Pharmaceuticals, Allergan Inc.

News Well, Mergers & Acquisitions, Wall Street Beat

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/TnK9Mi